Characteristics | General (n = 2,947) | Antineoplastic Drugs (n = 1,182) | Non-Antineoplastic Drugs (n = 1,671 | P-value |
---|---|---|---|---|
Total expense on lawsuit | 1,734.94 (232 – 7,792) | 7,508.83 (2,402 – 15,571) | 585.36 (86 – 2,635) | < 0.001 |
Unit price of medication | ||||
In dollars | 17.99 (1.94 – 142.23) | 64.91 (14.60 – 359.40) | 4.09 (0.53 – 65.87) | < 0.001 |
Sex | p-valuea = 0.019 | p-valuea = 0.131 | p-valuea = 0.007 | |
Male | 2,120.33 (245.16 – 8,761.78) | 8,654.14 (2,875,.79 –15,578.96) | 468.40 (54,11 – 2,546.65) | < 0.001 |
Female | 1,405.02 (220.92 – 6,621.09) | 6,492.30 (1,928.70 –15,410.61) | 618.53 (115.21 – 2,956.67) | < 0.001 |
Origin | p-valuea < 0.001 | p-valuea = 0.071 | p-valuea = 0.251 | |
Private | 993.83 (168.74 – 4,948.80) | 7,785.41 (3,244.89 –15,949.03) | 595.06 (116.96 – 1,646.50) | < 0.001 |
SUS | 2,482.45 (224.41 – 9,374.88) | 7,964.82 (2,875.79 –15,410.61) | 589.43 (81.66 – 3,556.58) | < 0.001 |
Philanthropic | 2,128.67 (315.25 – 8,633.58) | 6,475.23 (1,752.20 –14,170.84) | 448.04 (52.37 – 2,634.51) | < 0.001 |
Number of medications | ||||
One | 2,903 (98.5%) | 1,255 (99.7%) | 1,719 (97.8%) | < 0.001 |
Two | 33 (1.1%) | 0 (0%) | 31 (1.8%) | |
Three or more | 11 (0.4%) | 4 (0.3%) | 7 (0.4%) | |
Maximum duration of treatment | ||||
Months | 6 (3 – 9) | 5 (3 – 9) | 6 (3 – 9) | < 0.001 |